KR102392441B1 - 만성 신장 질환 환자의 유해한 심장 사건과 관련된 사망률 및 이환률 감소를 위한 시트르산 제2철 - Google Patents

만성 신장 질환 환자의 유해한 심장 사건과 관련된 사망률 및 이환률 감소를 위한 시트르산 제2철 Download PDF

Info

Publication number
KR102392441B1
KR102392441B1 KR1020167014000A KR20167014000A KR102392441B1 KR 102392441 B1 KR102392441 B1 KR 102392441B1 KR 1020167014000 A KR1020167014000 A KR 1020167014000A KR 20167014000 A KR20167014000 A KR 20167014000A KR 102392441 B1 KR102392441 B1 KR 102392441B1
Authority
KR
South Korea
Prior art keywords
ferric citrate
iron
patient
ckd
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167014000A
Other languages
English (en)
Korean (ko)
Other versions
KR20160096597A (ko
Inventor
엔리케 포라도수
론 벤처
제임스 에프. 3세 올리비에로
Original Assignee
케릭스 바이오파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케릭스 바이오파마슈티컬스 인코포레이티드 filed Critical 케릭스 바이오파마슈티컬스 인코포레이티드
Publication of KR20160096597A publication Critical patent/KR20160096597A/ko
Application granted granted Critical
Publication of KR102392441B1 publication Critical patent/KR102392441B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020167014000A 2013-11-04 2014-11-03 만성 신장 질환 환자의 유해한 심장 사건과 관련된 사망률 및 이환률 감소를 위한 시트르산 제2철 Active KR102392441B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (2)

Publication Number Publication Date
KR20160096597A KR20160096597A (ko) 2016-08-16
KR102392441B1 true KR102392441B1 (ko) 2022-05-02

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167014000A Active KR102392441B1 (ko) 2013-11-04 2014-11-03 만성 신장 질환 환자의 유해한 심장 사건과 관련된 사망률 및 이환률 감소를 위한 시트르산 제2철

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TW202203910A (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP2022505697A (ja) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー／エス カルボキシマルトース第二鉄による鉄欠乏症の治療
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
CN117999069A (zh) * 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
EP2590655B1 (en) * 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
TWI744215B (zh) 2021-11-01
JP2016535780A (ja) 2016-11-17
TW202203910A (zh) 2022-02-01
JP2021073230A (ja) 2021-05-13
SG11201603091QA (en) 2016-05-30
IL245317A0 (en) 2016-06-30
US20160256486A1 (en) 2016-09-08
HK1223031A1 (zh) 2017-07-21
JP6828100B2 (ja) 2021-02-10
MX2016005734A (es) 2016-11-08
AU2014341975A1 (en) 2016-05-19
WO2015066593A1 (en) 2015-05-07
CA2928200A1 (en) 2015-05-07
KR20160096597A (ko) 2016-08-16
EP3065734A1 (en) 2016-09-14
JP2019206562A (ja) 2019-12-05
BR112016009901A8 (pt) 2020-04-14
EP3065734A4 (en) 2017-05-17
CN105873583A (zh) 2016-08-17
TW201609088A (zh) 2016-03-16
US20190307791A1 (en) 2019-10-10
US20250360167A1 (en) 2025-11-27
EA201690926A1 (ru) 2016-09-30
EP3747432A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
KR102392441B1 (ko) 만성 신장 질환 환자의 유해한 심장 사건과 관련된 사망률 및 이환률 감소를 위한 시트르산 제2철
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20180071243A1 (en) Use of ferric citrate in the treatment of iron-deficiency anemia
JP7598885B2 (ja) 心血管有害事象のリスクのある対象における鉄欠乏症の処置
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5